Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.16199
Abstract: Key Points Question Is there a difference in survival or toxic effects between the main first-line therapies used for metastatic pancreatic cancer? Findings In this comparative effectiveness study that included 1102 patients, FOLFIRINOX (combined leucovorin… read more here.
Keywords: gemcitabine plus; metastatic pancreatic; plus nab; first line ... See more keywords
Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2024 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-024-08910-8
Abstract: Ramucirumab (RAM) is recommended as premedication with H1-receptor antagonists (H1RA) to prevent infusion-related reactions (IRRs). However, RAM is a human antibody with a low incidence of IRRs. We evaluated the noninferiority of non-H1RA (dexamethasone [DEX]… read more here.
Keywords: cancer; infusion related; premedication; gastric cancer ... See more keywords
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Drugs"
DOI: 10.1007/s40265-020-01295-y
Abstract: Atezolizumab (Tecentriq ® ), an immune checkpoint inhibitor against programmed death ligand 1 (PD-L1), is the first immunotherapy agent to be approved (for use in combination with nab-paclitaxel) in the USA, the EU (as first-line)… read more here.
Keywords: nab paclitaxel; combination nab; advanced triple; plus nab ... See more keywords
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of geriatric oncology"
DOI: 10.1016/j.jgo.2021.06.011
Abstract: OBJECTIVES This study aimed to examine the efficacy and safety of gemcitabine plus nab-paclitaxel (GnP) in older patients with metastatic pancreatic cancer (MPC), especially those ≥75 years old. MATERIALS AND METHODS This study retrospectively enrolled… read more here.
Keywords: nab paclitaxel; group; study; plus nab ... See more keywords
Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
Sign Up to like & getrecommendations! Published in 2019 at "Scientific Reports"
DOI: 10.1038/s41598-019-52486-x
Abstract: Overall survival in a phase III study for metastatic pancreatic cancer has significantly improved with gemcitabine (GEM) plus nab-paclitaxel. However, to date, there is limited data on the efficacy and safety of its use for… read more here.
Keywords: nab paclitaxel; gem plus; pancreatic cancer; plus nab ... See more keywords
Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14394
Abstract: We conducted a phase II study of carboplatin plus nab‐paclitaxel for the treatment of small cell lung cancer (SCLC) after the failure of a prior standard chemotherapy containing platinum, etoposide, irinotecan, and amrubicin if indicated.… read more here.
Keywords: plus nab; nab paclitaxel; phase study; study ... See more keywords
Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study
Sign Up to like & getrecommendations! Published in 2020 at "BMC Cancer"
DOI: 10.1186/s12885-020-07462-4
Abstract: Background Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer. Although UC has been considered a highly aggressive malignancy, no clinical studies have addressed the efficacy of chemotherapy for unresectable UC.… read more here.
Keywords: nab paclitaxel; gemcitabine; study; plus nab ... See more keywords
Clinical outcomes of gemcitabine plus nab-paclitaxel (GnP) in initially diagnosed locally advanced pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.407
Abstract: 407Background: Gemcitabine plus nab-Paclitaxel has shown improved survival in patients with metastatic pancreatic cancer in MPACT. Many studies have been investigating the survival benefit of GnP in LACP patients. The aim of this study is… read more here.
Keywords: gemcitabine plus; nab paclitaxel; pancreatic cancer; plus nab ... See more keywords
Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.523
Abstract: 523Background: Gemcitabine plus nab-paclitaxel (GnP) treatment is recommended for metastatic pancreatic adenocarcinoma (PDAC), and has been widely spread in our clinics. However, the usefulness for the patients with locally advanced PDAC is still controversial. We… read more here.
Keywords: nab paclitaxel; plus nab; level; locally advanced ... See more keywords
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.4017
Abstract: 4017 Background: FOLFIRINOX, consisting of leucovorin (LV), fluorouracil (FU), irinotecan (IRI) and oxaliplatin (L-OHP), and GnP, consisting of gemcitabine (GEM) plus nab-paclitaxel (nPTX), have shown superior efficacy over GEM in patients (pts) with metastatic pancreatic… read more here.
Keywords: arm; year; nab paclitaxel; plus nab ... See more keywords
Efficacy and safety of sitagliptin, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e16329
Abstract: e16329 Background: Chemoresistance is the main reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Thus, there is an urgent need to identify new targets and compounds to overcome chemotherapeutic resistance. Methods: The high-throughput… read more here.
Keywords: previously untreated; nab paclitaxel; sitagliptin; gnp ... See more keywords